Histopathological gastric mucosal changes in patients using proton pump inhibitors

Abstract

As a result of the widespread use of proton pump inhibitors (PPI), parietal cell hyperplasia/ hypertrophy (PCH/H) and a significant increase in fundic gland polyp (FGP) is observed in gastric mucosa in recent years. The aim of this study is to evaluate clinical and histopathological results of patients diagnosed with PCH/H and FGP. Clinical data and archieved slides of 60 patients who were diagnosed with PCH/H or FGP at our institution between 2012-2019 were reviewed. Of the patients included in the study , 40 were women and 20 were men. Thirty-three cases, diagnosed with PCH/H and 27 cases diagnosed with FGP were investigated. H. Pylori gastritis was seen in 6 cases. In one case with a FGP, micronodular-linear neuroendocrine cell hyperplasia was observed. The FGPs, developing in the later stages of PPI use, are identified by endoscopic and pathological findings. Enterocromafine cell-like hyperplastic changes can become apparent in patients using PPI. H. Pylori gastritis was found to be less common in patients diagnosed with FGP and PCH/H than in the general population. [Med-Science 2020; 9(1.000): 128-31]

Keywords

• parietal cell hyperplasia
• proton pump inhibitor
• fundic gland polyp
• neuroendocrine cell